# AstraZeneca's next-gen hopeful for a rare bone condition fails pivotal trial - Date: 2026-03-31 - Category: Biotech & Life Sciences AstraZeneca called it a success. The adult HPP trial missed its goal—but a subgroup of patients who developed the disease as children did show benefit. The problem: 80 percent of HPP patients are adults. ---